Nanoparticle-Mediated Delivery of Deferasirox: A Promising Strategy Against Invasive Aspergillosis

• DOI: 10.20944/preprints202410.0283.v1
• Publication Date: 2024-10-09T03:13:42Z
• Authors: Sydney Peppe; Moloud Farrokhi; Evan A. Waite; Mustafa Muhi; Efthymia Iliana M...
• Keywords: Deferasirox; Delivery system

BACKGROUND. Invasive aspergillosis (IA) is a deadly fungal lung infection. Antifungal resistance and treatment side effects are major concerns. Iron chelators vital for IA management, but systemic use can cause effects. We developed nanoparticles (NPs) to selectively deliver the iron chelator deferasirox (DFX) treatment. METHODS DFX was encapsulated in poly(lacticco‐ glycolic acid) (PLGA) NPs using single emulsion solvent evaporation method. were characterized by light scattering electron microscopy. loading efficiency release assessed spectrophotometrically. Toxicity evaluated SRB, luciferase, XTT assays. Therapeutic efficacy tested an mouse model, assessing burden qPCR biodistribution via imaging.RESULTS DFX‐NPs had size of ~50nm charge ~‐30mV, with ~90%. Release kinetics showed diffusion bioerosion. The EC50 significantly lower (p<0.001) than free drug, they less toxic (p<0.0001) mammalian cell cultures. In vivo, reduced Af (p<0.05). CONCLUSION designed effectively target kill minimal toxicity cells. significant vivo therapeutic suggests these could be safe effective IA.